Carlsmed, Inc. (CARL) – What Are Researchers Thinking About This Stock?

Shares of Carlsmed, Inc. (NASDAQ:CARL) have been given an average recommendation of “Moderate Buy” by the six brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $19.50.

A number of analysts have recently issued reports on the stock. Truist Financial increased their price target on shares of Carlsmed from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen upgraded shares of Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. BTIG Research increased their target price on shares of Carlsmed from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Finally, Weiss Ratings raised shares of Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th.

Institutional Trading of Carlsmed

Hedge funds and other institutional investors have recently modified their holdings of the company. Zevenbergen Capital Investments LLC increased its position in Carlsmed by 50.4% in the 3rd quarter. Zevenbergen Capital Investments LLC now owns 17,900 shares of the company’s stock worth $252,000 after purchasing an additional 6,000 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of Carlsmed during the 2nd quarter worth about $108,000. Jupiter Topco LLC acquired a new stake in shares of Carlsmed during the 2nd quarter valued at about $12,992,000. Parkman Healthcare Partners LLC acquired a new stake in shares of Carlsmed during the 2nd quarter valued at about $6,200,000. Finally, Alpine Woods Capital Investors LLC bought a new stake in shares of Carlsmed in the 2nd quarter valued at approximately $161,000.

Carlsmed Stock Down 4.1%

NASDAQ:CARL opened at $14.40 on Wednesday. The business’s fifty day moving average price is $14.98 and its 200 day moving average price is $12.46. The firm has a market capitalization of $393.12 million, a price-to-earnings ratio of -10.07 and a beta of 1.97. The company has a current ratio of 8.84, a quick ratio of 8.66 and a debt-to-equity ratio of 0.18. Carlsmed has a 1-year low of $8.50 and a 1-year high of $17.23.

Carlsmed (NASDAQ:CARL) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. The firm had revenue of $18.94 million during the quarter. Carlsmed had a negative return on equity of 38.06% and a negative net margin of 57.42%. On average, sell-side analysts forecast that Carlsmed will post -1.50 earnings per share for the current fiscal year.

About Carlsmed

Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company combines patient-specific planning, advanced imaging, software and additive manufacturing to develop implants designed to address the anatomical needs of individual patients.

Its products include the aprevo® patient-specific interbody implant system, which is designed for use in spinal fusion procedures. Carlsmed’s technology is intended to support surgeons in planning procedures and selecting or creating implants that may help restore spinal alignment and improve surgical precision.

Carlsmed serves the spine-care market through relationships with spine surgeons, hospitals and other healthcare providers.